Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study.
Nishibori Y, Kenmotsu H, Ando K, Tonsho A, Matsuda S, Morita M, Sekikawa M, Doshita K, Morikawa N, Miura K, Kodama H, Yabe M, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Harada H, Takahashi T. Nishibori Y, et al. Among authors: yabe m. Cancer Treat Res Commun. 2024;41:100849. doi: 10.1016/j.ctarc.2024.100849. Epub 2024 Nov 8. Cancer Treat Res Commun. 2024. PMID: 39536390 Free article.
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Mamesaya N, Muramatsu K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Sugino T, Shimizu T, Gon Y, Takahashi T. Mamesaya N, et al. Among authors: yabe m. Int J Clin Oncol. 2021 Apr;26(4):659-669. doi: 10.1007/s10147-020-01856-x. Epub 2021 Jan 7. Int J Clin Oncol. 2021. PMID: 33415571
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Kodama H, et al. Among authors: yabe m. Cancer Med. 2021 Nov;10(21):7503-7513. doi: 10.1002/cam4.4268. Epub 2021 Sep 29. Cancer Med. 2021. PMID: 34587359 Free PMC article.
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Nishimura A, Ono A, Wakuda K, Kawabata T, Yabe M, Miyawaki T, Miyawaki E, Kodama H, Nishioka N, Mamesaya N, Kobayashi H, Omori S, Kenmotsu H, Naito T, Murakami H, Harada H, Takahashi T. Nishimura A, et al. Among authors: yabe m. Invest New Drugs. 2022 Apr;40(2):403-410. doi: 10.1007/s10637-021-01191-6. Epub 2021 Oct 11. Invest New Drugs. 2022. PMID: 34633575 Free PMC article.
Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer.
Iida Y, Wakuda K, Kawata T, Morita M, Sekikawa M, Doshita K, Yabe M, Kodama H, Miura K, Morikawa N, Mamesaya N, Kobayashi H, Ko R, Ono A, Kenmotsu H, Naito T, Murakami H, Gon Y, Takahashi T. Iida Y, et al. Among authors: yabe m. Thorac Cancer. 2024 Feb;15(6):477-485. doi: 10.1111/1759-7714.15218. Epub 2024 Jan 19. Thorac Cancer. 2024. PMID: 38243641 Free PMC article.
Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study.
Morikawa N, Naito T, Morita M, Sekikawa M, Doshita K, Yabe M, Kodama H, Miura K, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takahashi T. Morikawa N, et al. Among authors: yabe m. J Geriatr Oncol. 2024 Sep;15(7):101832. doi: 10.1016/j.jgo.2024.101832. Epub 2024 Jul 12. J Geriatr Oncol. 2024. PMID: 38997933 Free article.
Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.
Doshita K, Naito T, Matsuda S, Morita M, Sekikawa M, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Ono A, Murakami H, Kenmotsu H, Takahashi T. Doshita K, et al. Among authors: yabe m. Thorac Cancer. 2024 Sep;15(25):1831-1841. doi: 10.1111/1759-7714.15403. Epub 2024 Jul 29. Thorac Cancer. 2024. PMID: 39075850 Free PMC article.
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H, Yabe M, Morikawa N, Iida Y, Mamesaya N, Kobayashi H, Ko R, Wakuda K, Kenmotsu H, Naito T, Murakami H, Isaka M, Ohde Y, Takahashi T. Morita M, et al. Among authors: yabe m. Cancer Rep (Hoboken). 2024 Sep;7(9):e70004. doi: 10.1002/cnr2.70004. Cancer Rep (Hoboken). 2024. PMID: 39245880 Free PMC article.
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Kodama H, et al. Among authors: yabe m. Invest New Drugs. 2021 Apr;39(2):571-577. doi: 10.1007/s10637-020-01005-1. Epub 2020 Sep 21. Invest New Drugs. 2021. PMID: 32955628
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Gon Y, Takahashi T. Wakuda K, et al. Among authors: yabe m. Lung Cancer. 2021 Jan;151:60-68. doi: 10.1016/j.lungcan.2020.11.009. Epub 2020 Nov 15. Lung Cancer. 2021. PMID: 33246646
331 results